Join us for a free webinar covering the latest information on aggressive NHL, treatment advances, side effects management and the value of open communication with your treatment team. Speaker is Dr. Monica Mead, Assistant Clinical Professor, UCLA.
Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP). The therapy, KTE-C19, being developed by Kite Pharma, is another example of a chimeric antigen receptor (CAR), an approach that genetically engineers patients’ immune T cells and reintroduces them into the body to kill cancer cells. KTE-C19 is crafted by removing patients' T cells and geneti...
Beat AML is a collaboration launched nearly three years ago by LLS and the Knight Cancer Institute at Oregon Health & Science University (OHSU), to go on the offenensive against acute myeloid leukemia (AML), a blood cancer with a poor prognosis and little change in the standard of care in 40 years. More than a dozen abstracts from the first phase of the initiative will be featured throughout the American Society of Hematology (#ASH15) Annual Meeting in Orlando over the next few days. #...
